August 15, 2025 a 04:39 pm
LLY: Analysts Ratings - Eli Lilly and Company
Eli Lilly and Company, headquartered in Indianapolis, has a diverse product portfolio catering to various medical needs, ranging from diabetes management to oncology, and more. Despite the challenges in the pharmaceutical industry, Eli Lilly continues to show resilience. The analyst ratings provide insights into the stock’s potential, indicating a general optimistic sentiment with some caution reflected in recent months.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 18 | |
| Hold | 7 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
Over the past months, analyst ratings for Eli Lilly have shown some stability with notable shifts in categories. While "Buy" ratings have remained strong, there has been a noticeable decline in "Strong Buy" recommendations.
- From a peak in Strong Buy ratings, there’s a downward trend over the recent months from 8 to 4.
- Hold ratings have fluctuated, showing a slight increase, indicative of cautious optimism or awaiting further catalysts.
- The overall ratings volume has remained consistent, reflecting a steady interest among analysts.
Percentage Trends
The data reveal subtle shifts in analyst sentiment over time. Notably, there's an increasing tendency toward "Hold" positions.
- Strong Buy percentages fell from around 30% to 15% in recent months.
- Buy recommendations remain the majority, indicating ongoing confidence.
- Hold ratings have slightly increased, currently constituting about 30% of recommendations.
- These movements suggest a tilt towards more cautious optimism, less about immediate buys and more on strategic positions.
Latest Analyst Recommendations
Recent analyst recommendations show a continuity in sentiment, with most analysts maintaining their previous stance on Eli Lilly's stock.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-13 | Buy | Buy | Guggenheim |
| 2025-08-11 | Buy | Buy | Deutsche Bank |
| 2025-08-08 | Buy | Buy | UBS |
| 2025-07-11 | Buy | Buy | Guggenheim |
| 2025-07-10 | Overweight | Overweight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Changes in analyst recommendations underscore shifts in strategic perspectives. These adjustments may signal evolving market conditions or internal assessments.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-28 | Reduce | Buy | HSBC |
| 2025-04-08 | Buy | Neutral | Goldman Sachs |
| 2024-08-12 | Buy | Hold | Deutsche Bank |
| 2024-04-03 | Buy | Hold | Erste Group |
| 2024-02-21 | Hold | Buy | DZ Bank |
Interpretation
The analysis of Eli Lilly's stock ratings suggests a cautious optimism among analysts. Although there is stable confidence reflected in the majority of "Buy" recommendations, the increase in "Hold" ratings suggests some level of caution or anticipation of future market shifts. Recent changes in opinions highlight evolving perspectives, reflecting either internal corporate changes or broader industry-wide factors. Overall, Eli Lilly's analyst sentiment appears robust, yet attentive to ongoing developments in its business and the pharmaceutical landscape.
Conclusion
In conclusion, Eli Lilly's stock ratings reflect a mix of confident endorsement and cautious evaluation by analysts. While the prevailing sentiment is dominantly positive, marked by numerous "Buy" ratings, the shifts towards "Hold" indicate a prudence driven by market uncertainties or strategic reassessment. The company's broad product portfolio and significant collaborations continue to represent substantial growth potential. However, analysts seem to be hedging their bets, balancing optimism with a wait-and-see approach concerning future catalysts or earnings results. This nuanced view should guide investors in aligning their strategies with both current sentiment and potential developments.